Skip to content

Observational study of liposomes amphotericin B in the treatment of HIV related talaromyces marneffei infection

The efficacy and safety of liposomes amphotericin B for the treatment of HIV related talaromyces marneffei infection: a multicenter, prospective, observational cohort study

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400082350
Enrollment
Unknown
Registered
2024-03-27
Start date
2024-03-30
Completion date
Unknown
Last updated
2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Talaromycosis

Interventions

Liposome amphotericin B group (observed group):Induction period receiving treatment with liposomes amphotericin B
Amphotericin B deoxycholate group (control group):Induction period receiving treatment with Amphotericin B deoxycholate

Sponsors

The Fourth People's Hospital of Nanning
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age = 18 years old; 2. Confirmed HIV infection; 3.Diagnosis of Talaromyces marneffei infection, diagnostic criteria: ? Clinical syndromes with Talaromyces marneffei infection (fever, emaciation, anemia, lymph node enlargement, Liver and spleen enlargement, etc); ? Confirmed Talaromyces marneffei infection through blood culture; or ?Clinical blood samples show positive of Talaromyces marneffei by polymerase chain reaction (PCR);

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating female patients; 2. Liver dysfunction (baseline ALT and AST greater than 5 times the upper limit of normal values); 3. Severe renal insufficiency or the need for hemodialysis (creatinine clearance rate less than 30); 4. Co-infection with other systemic fungal infections with clear diagnostic evidence (cryptococcal, candidaemia, or mucor infection); 5. Patient diagnosed with tuberculosis and undergoing anti-tuberculosis treatment; 6. Paitent with mental illness or abnormal behavior; 7. Receive systemic antifungal therapy for 48 hours or more before enrollment; 8. Current participants in other clinical trials; 9. The researcher assessed that there are other factors not suitable for inclusion.

Design outcomes

Primary

MeasureTime frame
Clinical response rate at day 14;

Secondary

MeasureTime frame
All-cause mortality at day 14;Adverse events on day 14;Recurrence of Talaromyces marneffei infection;Incidence of immune reconstitution inflammatory syndrome (IRIS);

Countries

China

Contacts

Public ContactJun Zou

The Fourth People's Hospital of Nanning, Changqian Road, Xingning District, Nanning City, Guangxi Province

9134432@qq.com+86 771 263 7126

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026